cas 313339-92-3|| where to buy 3,5-dichloropyrazine-2-carbonitrile

Nom du produit:3,5-dichloropyrazine-2-carbonitrile

IUPAC Name:3,5-dichloropyrazine-2-carbonitrile

Unité d'emballage	Stock disponible	Prix($)
CM102418-10g	in stock	Ǝư
CM102418-25g	in stock	ŵǜƎ
CM102418-100g	in stock	ǜǜǶ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 313339-92-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:313339-92-3; Formule moléculaire:C5HCl2N3; Point de fusion:-; Code SMILES:ClC1=CN=C(C#N)C(Cl)=N1; Densité:

: Numéro de catalogue:CM102418; Poids moléculaire:173.98; Point d'ébullition:276.6°C at 760 mmHg; N° Mdl:MFCD13193460; Stockage:Keep in Inert atmosphere, store at 2-8°C.

: Pyrazines; Pyrazine is a heterocyclic aromatic organic compound with chemical formula C4H4N2. The marketed pyrazine drugs are mainly distributed in the field of anti-tumor and anti-infection. In recent years, there have been many new drugs in various fields, and there are some new target drugs worthy of attention.; pyrazine,pyrazine price; if you want to know the latest news about pyrazine and pyrazine price, please come to our website and get a quote for free.

: NX-2127; Existing BTK inhibitors directly bind to the active site of BTK and face challenges such as acquired resistance or incomplete responses over time. PROTAC-induced BTK degradation works as a novel alternative therapy for drug-resistant cancers. The latest journal Science publishes the identification of BTK mutations that are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Nurix Therapeutics’ TPD compound NX-2127 is a first-in-class, dual-function small-molecule protein degrader. It drives targeted BTK and transcription factor IKAROS (IKZF1/3) degradation through ubiquitination and proteasomal degradation, adding combined benefit. NX-2127 is under development of phase I clinical trials that shows promising results and a manageable safety profile for the treatment of relapsed/ refractory B-cell malignancies.

: NX-5948; Nurix announced the presentation of the first findings of clinical responses in the brain for NX-5948. NX-5948 is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. NX-5948 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.